Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iRhythm Holdings, Inc. filings document the public-company reporting of a digital health care business centered on ambulatory cardiac monitoring. Recent Form 8-K disclosures report operating results, financial condition, guidance-related exhibits, Regulation FD materials, material agreements, executive compensation policy changes, board appointments, and changes in the independent registered public accounting firm.
Proxy materials cover director elections, board and committee structure, executive compensation, equity awards, and stockholder voting matters. The filing record also documents the completed holding-company reorganization under which iRhythm Holdings became successor registrant to iRhythm Technologies, including common-stock continuity and predecessor registration-termination records.
iRhythm Holdings Chief Financial Officer Daniel G. Wilson reported RSU vesting and related share sales. On February 24, 2026, he acquired 9,412 shares of common stock at no cost upon the Compensation & Human Capital Management Committee determining performance RSU conditions were met. On February 25, 2026, he sold 5,188 shares at an average price of $135.4189 to cover tax withholding and remittance obligations from the RSU vesting. After these transactions, he directly held 30,694 shares and indirectly held 100 shares through The Wilson Living Trust, where he serves as trustee.
iRhythm Holdings executive Minang Turakhia, Chief Medical/Scientific Officer and EVP Advanced Technology, reported a mix of equity award and related share sale. On February 24, 2026, he acquired 15,060 shares of common stock at $0.00 per share through the vesting of performance RSUs granted on February 27, 2023, after the compensation committee determined the performance conditions were met. On February 25, 2026, he sold 7,804 shares at an average price of $135.4189 per share to cover tax withholding and remittance obligations tied to this vesting. Following these transactions, he directly held 48,899 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive vice president Mervin Smith reported performance-based equity vesting and related tax sales of company stock. He acquired 9,210 shares of common stock on February 24, 2026 at $0.00 per share from performance RSUs after a board committee determined the performance conditions were met.
On February 25, 2026, he sold 4,041 shares of common stock at an average price of $135.4189 per share to cover tax withholding and remittance obligations tied to the RSU vesting. After these transactions, he directly owned 20,275 shares of iRhythm common stock.
iRhythm Holdings EVP and Chief Risk Officer Sumi Shrishrimal reported equity compensation activity and a related tax sale. On February 24, 2026, she acquired 11,294 shares of common stock at $0.00 per share from performance RSUs granted on February 27, 2023, after the board committee determined performance conditions were met. This increased her direct holdings to 45,399 shares. On February 25, 2026, she sold 6,217 shares of common stock at an average price of $135.4189 per share, leaving 39,182 shares held directly. A footnote states these shares were sold to cover tax withholding and remittance obligations tied to the vesting of the performance RSUs.
iRhythm Holdings, Inc. Chief Accounting Officer Marc Wade Rosenbaum reported two transactions in common stock. On February 24, 2026, he acquired 9,210 shares at $0.00 per share through a grant determined by the board’s Compensation & Human Capital Management Committee after performance conditions for previously granted performance RSUs were met. On February 25, 2026, he sold 4,797 shares at an average price of $135.4189 per share to cover tax withholding and remittance obligations related to the vesting of those performance RSUs. Following these transactions, he directly owned 15,014 shares of iRhythm common stock.
iRhythm Holdings executive Chad Patterson reported a mix of stock transactions. On February 24, 2026, he acquired 17,318 shares of common stock at $0.00 per share through the vesting of performance RSUs, after the board’s Compensation & Human Capital Management Committee determined performance conditions for RSUs granted on February 27, 2023 were met. On February 25, 2026, he sold 8,967 shares of common stock at an average price of $135.4189 per share to cover tax withholding and remittance obligations related to that vesting. Following these transactions, he directly owned 51,738 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive Patrick Michael Murphy, the company’s CBO and CLO, acquired 15,060 shares of common stock on a grant/award basis after performance conditions were met for previously granted performance RSUs. On the following day, he sold 7,805 shares in open-market transactions at an average price of $135.4189 per share to cover tax withholding and remittance obligations related to the vesting. After these transactions, he directly owned 60,536 shares of iRhythm common stock.
iRhythm Holdings President and CEO Quentin S. Blackford reported a performance-based stock vesting and related tax sale. On February 24, he acquired 46,687 shares of common stock at no cost through the vesting of performance RSUs granted on February 27, 2023, after the board committee determined the performance conditions were met.
On February 25, he sold 25,540 shares of common stock at an average price of $135.4189 per share solely to cover tax withholding and remittance obligations tied to that vesting. After these transactions, he directly owned 186,126 shares of iRhythm common stock.
iRhythm Holdings, Inc. Chief Accounting Officer Marc Wade Rosenbaum reported an open-market sale of 280 shares of common stock at an average price of $140.91 per share on February 24, 2026. After this sale, he directly holds 10,601 shares of iRhythm common stock.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan that he established on May 12, 2025 and modified on November 25, 2025, which is designed to allow systematic share sales according to preset instructions.
iRhythm Holdings, Inc. executive vice president of strategic business operations Mervin Smith reported an open-market sale of common stock. On February 24, 2026, he sold 732 shares at an average price of $140.91 per share.
After this transaction, Smith directly owned 15,106 shares of iRhythm common stock. The sale was executed under a pre-established Rule 10b5-1 trading plan that Smith adopted on November 19, 2025, indicating the trades were made according to a predetermined schedule.